Ligand Pharmaceuticals (LGND) reported Q4 core adjusted net income Thursday of $1.27 per diluted share, up from $1.05 a year earlier.
Analysts polled by FactSet expected $1.19.
Total revenue for the quarter ended Dec. 31 was $42.8 million, up from $28.1 million a year earlier.
Analysts surveyed by FactSet expected $39 million.
The company expects full year 2025 adjusted earnings in a range of $6.00 to $6.25 per diluted share on total revenue of $180 million to $200 million. Analysts polled by FactSet expect adjusted earnings of $6.07 per diluted share on total revenue of $187.1 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。